Drug intelligence / Profile preview

GH509

Development stage: Phase 2
Lead developer: Quotient Sciences
Modality: Nucleic Acid Therapeutics, Small Molecules
Administration: Oral

Overview

GH509 is an investigational drug developed by 1Globe Biomedical for the treatment of nonalcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD). It is currently in Phase 1/2 clinical trials. The drug is classified as a hepatoprotectant, but its precise mechanism of action has not been defined. GH509 is administered orally and has not received orphan drug designation or regulatory approval to date[1][2][3][5]. Clinical studies are ongoing to evaluate its efficacy and safety in adult patients with NASH or NAFLD[5][7].

Beyond the preview

Go deeper on GH509.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GH509.

Explore the full profile